I am the Global Head of Oncology, Medical in AstraZeneca’s Oncology Business Unit, helping to drive our vision to redefine cancer care.  We advance the practice of cancer care through robust evidence generation, scientific partnerships and helping to reimagine the future cancer care paradigm.  澳门第一赌城在线娱乐以科学为中心的方法以及证据为临床医生和患者在决策过程中建立了信心.

在担任现职之前,我领导澳门在线赌城娱乐在乳腺癌方面的全球研究和开发. As part of that work, I led the development and execution of our breast cancer strategy, establishing the tumour council model, 设计并建立了澳门第一赌城在线娱乐行业领先的乳腺癌临床开发项目.

I joined AstraZeneca after nearly 15 years as a Medical Oncologist, focusing on breast and lung cancer. I achieved international recognition for my research and educational leadership, 其中包括担任许多乳腺癌关键试验的首席研究员包括几项改变实践的三期试验. 我的作品发表在超过125篇同行评议的手稿中,包括《澳门在线赌城娱乐》, The Lancet, Journal of Clinical Oncology and Cancer. 我还领导和创建了许多肿瘤学方面的创新教育项目,并获得了多个教学和指导奖.

In addition to the impact on clinical research and clinical care, I am proud of my role as a mentor to clinicians and cancer research pioneers. Over my career, I have mentored more than 100 residents, 看到他们中的许多人成为全球癌症中心的领导者,我感到非常荣幸.

I have chaired, 加拿大许多区域和国家卫生服务癌症领导委员会以及国际癌症会议领导委员会的共同主席或成员, with a focus on driving improved patient outcomes across the world.

在加拿大阿尔伯塔大学获得内科和肿瘤学医学学位和研究生培训后, I earned a Masters in Medical Education at the University of Southern California. My training in breast cancer included a fellowship at the University of Toronto.

在我的职业生涯中,我一直在努力做出改变,为癌症患者带来真正的好处. 澳门第一赌城在线娱乐正处于一个前所未有的时代,癌症治疗领域正处于彻底改变的边缘, 我相信澳门在线赌城娱乐的团队将在塑造澳门第一赌城在线娱乐的愿景和与肿瘤界合作实现这一愿景方面发挥关键作用. 澳门第一赌城在线娱乐一流的研究项目涵盖抗体药物偶联物等领域, DNA damage response, immuno-oncology, tumor drivers and resistance, 此外,澳门第一赌城在线娱乐的数字专业知识和合作方式使澳门第一赌城在线娱乐处于一个独特的位置,使澳门第一赌城在线娱乐的雄心壮志成为现实.

Sunil Verma Senior Vice President, Global Head of Oncology, Medical, AstraZeneca

Top 25 Young Breast Oncologists in the World (2006)

未来论坛奖旨在表彰年轻的肿瘤学家,他们将成为未来乳腺癌领域的领导者

Outstanding Teaching Award (2005, 2007, 2011)

多伦多大学医学院医学系肿瘤内科

Distinguished Alumni Award

University of Alberta

CURRENT ROLE

Senior Vice President, Global Head of Oncology, Medical at AstraZeneca

2019-2021

曾担任澳门在线赌城娱乐公司乳腺癌研究战略主管和全球乳腺癌临床主管, responsible for leading the company’s research and development in breast cancer

2015-2019

领导了部门的发展,并启动了新卡尔加里癌症中心的建设, 在担任卡尔加里大学肿瘤科教授和主任以及汤姆·贝克癌症中心医学主任期间,他是北美最大的综合性癌症护理机构之一

2004-2015

Served on the faculty at the University of Toronto, most recently as Associate Professor, Department of Medicine

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H. N Engl J Med. 2018 Nov 15;379(20):1926-36.

http://www.nejm.org/doi/full/10.1056/NEJMoa1810527

帕博西尼联合内分泌治疗老年女性HR+/ her2晚期乳腺癌:一项随机PALOMA临床研究的汇总分析

Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W. Iyer S, Schnell P, Bartlett CH, Johnston S. Eur J Cancer. 2018 Sep 1;101:123-33.

http://www.ejcancer.com/article/S0959-8049(18)30908-0/fulltext

激素受体阳性绝经后妇女的健康相关生活质量, 核糖环尼+来曲唑治疗人表皮生长因子受体2阴性晚期乳腺癌:MONALEESA-2的结果

Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W. Breast Cancer Res Treat. 2018 Aug1;170(3):535-45.

http://link.springer.com/article/10.1007%2Fs10549-018-4769-z

曲妥珠单抗emtansine与卡培他滨+拉帕替尼在先前治疗过的her2阳性晚期乳腺癌(EMILIA)患者中的治疗:一项随机分组的最终总生存结果的描述性分析, open-label, phase 3 trial

Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Lancet Oncol. 2017 Jun;18(6):732–742.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30312-1/fulltext

帕博西尼联合富维司汀治疗激素受体阳性/ her2阴性晚期转移性乳腺癌:来自多中心的详细安全性分析, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

Verma S, Bartlett CH, Schnell P, Demichele AM, Loi S, Ro J, Colleoni M, Iwata  H, Harbeck N, Cristofanilli M, Zhang K, Thielse A, Turner NC, Rugo HS. Oncologist. 2016 Oct;21(10):1165-75.

http://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2016-0097

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group, N Engl J Med. 2012 Nov 8;367(19):1783-91.

http://www.nejm.org/doi/full/10.1056/NEJMoa1209124

加拿大三阴性乳腺癌治疗新趋势:一项调查

Verma S, Provencher L, Dent R, Curr Oncol. 2011 Aug 03;18(4):180-90.

http://current-oncology.com/index.php/oncology/article/view/913

 

Patient adherence to aromatase inhibitor treatment in the adjuvant setting

Verma S, Madarnas Y, Sehdev S, Martin G, Bajcar J. Curr Oncol. 2011 May;18 Suppl 1:S3-9.

http://current-oncology.com/index.php/oncology/article/view/899

在目前的乳腺癌细胞毒性和靶向药物试验中,心脏毒性是否得到了充分的评估?

Verma S, Ewer MS. Ann Oncol. 2011 May;22(5):1011-8.

http://www.annalsofoncology.org/article/S0923-7534(19)38535-7/fulltext


Veeva ID: Z4-37225
Date of preparation: November 2021